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Collaboration between  thymus  or  thymus-derived lymphocytes and  nonthymus- 
derived precursors  of  antibody-forming ceils  has  been  implicated in  the  immune 
response of mice to sheep erythrocytes (SRBC) I (1-3). Neonatal thymectomy impairs 
the response of mice to SRBC, and this can be reversed by inoculating thymus or 
thoracic duct lymphocytes simultaneously with SRBC  (4, 5). In  this system, thymus 
cells were as effective as thoracic duct cells and semiallogeneic cells were also effective. 
The identity of the antibody-forming cells produced was determined by using anti-H2 
sera in allogeneically reconstituted hosts and chromosome marker analysis in a  syn- 
geneic system. These techniques demonstrated that the antibody-forming cells were, 
in  general,  derived not  from  the  inoculated lymphocytes,  but  from  cells  already 
present in thymectomized hosts. Irradiated recipients of lymphoid cells from various 
sources were used to identify the precursors of antibody-forming cells. Thymus cells 
given together with SRBC failed to produce antibody-forming cells in irradiated mice, 
even when injected in very large numbers. A synergistic effect between thymus and 
marrow cells has, however, been described in such mice (6). By means of a chromosome 
marker method it was shown that all the antibody-forming cells produced were derived 
not from the thymus donor, but from the marrow donor (7). The capacity of adult 
thymectomized irradiated and marrow-protected mice to  respond  to  SRBC  is  de- 
pressed but can be restored by the injection of thoracic duct lymphocytes (5). Semi- 
allogeneic lymphocytes were effective in this system, and it was shown, by means of 
anti-H2 sera, that the antibody-forming cells produced were again derived not from 
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the  inoculated  lymphocytes,  but  from  the  marrow.  It  is  evident,  therefore,  that 
collaboration between thymus-derived ,and  marrow-derived cells is an essential com- 
ponent of the response of mice to SRBC. More recent experiments have shown that 
a  similar  type  of  collaboration  takes  place  with  respect  to  other  antigens,  such  as 
heterologous serum albumin (8). 
The  nature  of  the interaction  which  takes  place between  thymus  and  non- 
thymus-derived  lymphocytes is not understood.  Clearly, the antibody-forming 
cell precursor  is not thymus-derived  (4,  5,  7),  but it is not known  whether  the 
thymus-derived  cell,  the  nonthymus-derived  cell,  or  both,  can  recognize  and 
react  specifically  with  antigen,  and  thus  determine  the  specificity  of  the  re- 
sponse. In an attempt to study this question, experiments were performed with 
mice rendered  specifically tolerant  of SRBC.  In this paper,  we present  results 
which  indicate  that  target  cells for  tolerance  induction  exist  in  the  thymus- 
derived lymphocyte population. They cannot, however, be demonstrated in the 
nonthymus-derived  population in the system used here. These findings are dis- 
cussed with reference to the nature of the interaction which takes place between 
the two classes of lymphoid cells. 
Materials  and Methods 
Animals.--Male and female mice of the highly inbred CBA strain, originally obtained from 
Harwell, Didcot, Berkshire, England, were used. They were raised and maintained at the Hall 
Institute and were fed Barastoc cubes with an occasional green feed supplement of cabbage 
and  water ad libitum.  Neonatally  thymectomized mice were reared on foster mothers  of a 
randomly bred Hall Institute strain with a view to minimizing losses from cannibalism after 
the operation. Penicillin, at a dose level of 600,000 units per liter, was added to the drinking 
water each day. 
Cell Suspensions.--Cell  suspensions  from thymus, spleen,  and mesenteric lymph nodes were 
prepared by teasing with fine forceps through an 80-mesh stainless steel sieve in cold Eisen's 
solution. 2 Further disruption was achieved by gentle aspiration with a Pasteur pipette. The 
suspensions  of single cells were washed three times in Eisen's solution in the case of thymus and 
once or twice in the case of lymph nodes or spleen. The cells were finally resuspended in Eisen's 
solution and counted in a hemocytometer, the volume being adjusted so that the number of 
cells required for injection was contained in 0.2~).6 ml, depending on the experiment. 
Marrow cells were expressed  from the femurs and tibiae by means of a syringe and a needle 
using cold Eisen's solution. The marrow plugs were gently disrupted by aspiration through a 
25-gauge needle.  The suspension  of single cells was washed once, resuspended in cold Eisen's 
solution, counted, and the volume adjusted so that the required dose could be injected. 
Thoracic duct lymphocytes were obtained from mice cannulated and restrained in modified 
Bollman cages. The ceils were collected in cold Dulbecco's solution ~ containing 10% fetal calf 
serum. 4 After gentle centrifugation, the cells were resuspended in a volume suitable for injec- 
tion. 
2 Kern, M., and H. N. Eisen. 1959. The effect of antigen stimulation  on incorporation of 
phosphate and methionine into proteins and isolated lymph node cells. J. Exp. Med. 110:207. 
Dulbecco, R., and M. Vogt. 1954. Plaque formation and isolation of pure lines with polio-* 
rnvelltis viruses..f. Exp. Meal. 90:167. 
4 Fetal  calf serum  was  obtained  from  Commonwealth  Serum  Laboratories,  Melbourne, 
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SRBC were obtained from a single animal. The jugular vein was punctured at weekly inter- 
vals, the blood collected, and stored in Alsever's solution for 1 wk prior to use. When required, 
the cells were washed three times in saline and finally resuspended in an appropriate volume. 
The number of cells used for immunization was 2-5 )<  10 s. Horse erythrocytes were obtained 
from Commonwealth Serum Laboratories, Melbourne, Australia, and stored in citrate saline. 
When required, they were washed three times in saline and resuspended to an appropriate 
volume. The same number of cells was used for immunization as in the case of SRBC. 
Injections.--Cell suspensions were injected into the tail vein unless otherwise stated. In the 
case of thymus cells given in doses exceeding 10 million per mouse, it was absolutely essential 
to spread the injection over 1-2 min and to give a large volume (up to 0.6 ml) to prevent death 
from emboli. Mice were not heparinized before injection. 
Operative Procedures.--Thymectomy or sham-operation was performed in newborn mice, 
less than 36-hr old or in 8-10-wk old mice, according to the method of Miller (9). Whenever 
thymectomized mice were killed, the mediastinum was examined macroscopically and, in some 
cases microscopically, to check for the presence of thymus remnants. Only very few mice were 
found with such remnants and were discarded from the experiments. 
The technique used to establish a  thoracic duct fistula has already been described in the 
first paper in this series (4). 
Irradiation.--Intact or adult thymectomized mice were exposed to total body irradiation in 
a Perspex box. In the case of thymectomized mice, irradiation was performed generally 1-2 wk 
after thymectomy. The dose given was 800 r  to midpoint with maximum backscatter condi- 
tions and the machine operated under conditions of 250 kv, 15 ma, and an HVL (half value 
layer) of 1 mm Cu. The focal skin distance was 50 cm and the absorbed dose rate was 170 r/ 
min. When thymectomized irradiated mice were to be protected with bone marrow, they re- 
ceived an intravenous injection of 3-5 million cells in 0.1 ml of Eisen's solution 1-3 hr after 
irradiation. All irradiated mice were given penicillin in the drinking water. 
Plaque Forming Cell (PFC) Assays.--Spleen cell suspensions for assays were prepared as 
mentioned above, washed once, and diluted to an appropriate volume in Eisen's solution so 
that 0.1 ml contained an estimated number of 100-500 plaque-forming cells. The actual num- 
ber of plaque-forming cells  was determined according to  the method of Cunningham and 
Szenberg (10).  In order to estimate the number of developed plaques, a  rabbit anti-mouse 
gammaglobulin serum was added to the reaction mixture in the assay. This number was de- 
rived, by difference, from assays done in the presence or absence of antiglobulin antibody. 
Induction of Immunological Tolerance to Sheep Erythrocytes.--8-12-wk old CBA mice were 
made tolerant of sheep erythrocytes according to the method of Dietrich and Dukor (11). They 
received one intraperitoneal injection of 0.5 ml of packed sheep erythrocytes and 24 hr later a 
subcutaneous injection of cyclophosphamide  5 in phosphate buffer in a dose of 1 mg per 10 g 
body weight. Control mice were injected only with cyclophosphamide. 
Statistical Analysis.--The geometric means and standard errors of the mean were calculated 
from the log10 of the plaque-forming cell counts. P  values were determined by the Rank test. 
In the comparison of the means of any two groups of observations, a significance level of 0.05 
was chosen. 
RESULTS 
Induction of Tolerance  to Sheep Erythrocytes.--8-12-wk  old CBA mice were 
given packed SRBC intraperitoneally and 24 hr later,  cyclophosphamide sub- 
,  cutaneously. Control mice received cyclophosphamide only. Three wk later the 
mice were challenged with a mixture of SRBC and horse red blood cells (HRBC) 
5 Cyclophosphamide (Endoxan, Asta), Charles McDonald, Caringbah, Australia. 5" 
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and the number  of direct and  indirect plaque-forming cells (PFC)  per spleen 
t~roduced against both SRBC  and HRBC  was determined at intervals from 2 
to 10 days after challenge. The results are shown in Figs. 1 and 2. It can be seen 
*hat the peak 19S response to SRBC  and to HRBC  occurred at 4  days after 
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FIG. 1.  Direct (19S) PFC produced in the spleens of CBA mice challenged with SRBC (O) 
and HRBC  (0) 3 wk after pretreatment with SRBC and cyclophosphamide  (.  ), or with 
cyclophosphamide alone (----). A  A  indicates the response of normal mice to SRBC. The 
number of mlce per point was 4-15. Geometric means are shown and the upper and lower limits 
of the standard error are indicated by the vertical bars. 
challenge in mice treated with cyclophosphamide alone and that pretreatment 
with both cyclophosphamide and SRBC did not significantly alter the response 
to HRBC,  but markedly depressed that  to  SRBC.  In  the case of developed 
PFC  the peak response was achieved at 6  days after challenge and, similarly, 679 
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Fzo. 2.  IrJdirect (developed)  PFC produced in the spleens of CBA mice challenged with 
SRBC  (O)  and  HRBC  (O)  3  wk  after pretreatment with  SRBC  and  cyclophosphamide 
(  ) or with cyclophosphamide  alone (---). A  A  indicates the response of normal mice 
to SRBC. The number of mice per point was 4-5. Geometric means are shown and the upper 
and lower limits of the standard error are indicated by the vertical bars. 680  CELL  TO  CELL  INTERACTION  IN  IMMUNE  RESPONSE.  V 
only the response to SRBC was markedly depressed by pretreatment with both 
cyclophosphamide and SRBC. 
The results shown in Figs. 1 and 2 indicate that recovery from the immuno- 
suppressive  effect  of cyclophosphamide was  evident  3  wk  after  pretreatment 
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FIG. 3. Direct (19S) 4--5 days PFC response per spleen of mice challenged with SRBC (O) 
and ItRBC (O) at various weekly intervals  after pretreatment  with SRBC and cyclophos- 
phamide (  ) or with cyclophosphamide alone (---). The number of mice per point was from 
4 to 12. Geometric means are shown and the upper and lower limits of the standard error are 
indicated by the vertical bars. 
with the drug alone. It was of interest  to determine how soon after such pre- 
treatment evidence of recovery could be noted and how long after pretreatment 
with both SRBC and  cyclophosphamide specific tolerance to SRBC could be 
expected. The results of a time course study on the 4-5 day 19S PFC response of 
mice pretreated with either cyclophosphamide alone or together with SRBC are 
shown in Fig. 3. It is evident that a significant response to heterologous erythro- 
cytes can be expected as early as 1 wk after pretreatment with the drug alone, 
and that a marked specific depression of the response to SRBC is maintained for j.  F.  A. P. MILLER  AND  G. F. MITCIIELL  681 
up to 4  wk after pretreatment with both drug and SRBC.  These rates of re- 
covery from the specific and nonspecific suppressive effects of cyclophosphamide 
are more rapid than those reported by others using higher doses of the drug and 
a different injection schedule (12). 
In  most  experiments,  therefore,  SRBC-cyclophosphamide-pretreated mice 
were used 2-3 wk after the tolerization regime. At that period, as can be seen 
from Table I, tolerance was strictly specific: SRBC-tolerant mice could produce 
a normal response to ttRBC, and HRBC-tolerant mice could produce a  normal 
response to SRBC. Furthermore, inducing the response to HRBC did not break 
tolerance to SRBC, when recipients were challenged simultaneously with both 
TABLE I 
19S PFC Response of CBA  Mice Pretreated with Cyclophosphamide and SRBC and 
Challen ed with SRBC and HRBC 
Pretreatment 
Day 1  Day 2 
SRBC  Cyclophos- 
phamide 
HRBC  Cyclophos- 
phamide 
--  Cyclophos- 
phamlde 
*,[I,  P  <  0.005. 
Erythrocytes used 
for challenge 
(days 21-28) 
SRBC 
HRBC 
SRBC +  HRBC 
SRBC 
HRBC 
SRBC +  HRBC 
SRBC 
HRBC 
SRBC +  HRBC 
19S PFC count 4-5 days after challenge 
Anti-SRBC 
PFC/spleen 
1,540(1,740-1,360)*~  (35)1 
80(110-60)  (6) 
950(1,240-720)[1  (11) 
92,200(104,610-81,270)  (8) 
14(16-11)  (8) 
101,850(111,400-93,130)  (8) 
94,570(110,270-81,110)*  (21) 
300(440-200)  (6) 
64,750(72,560-57,780)[[  (15) 
~: Geometric mean, upper and lower limits of sE. 
Anti-HRB  C 
PFC/spleen 
100 (too-so) $  (4) 
18,960(23,030-15,610)  (12) 
17,620(21,830-14,220)  (11) 
2(3-1)  (8) 
530(610-460)  (8) 
2,950(3,600-2,420) ¶  (8) 
260(310-210)  (6) 
22,110(27,300-17,910)  (14) 
29,730(34,400-25,690)¶  (15) 
§ Single number in parentheses refers to number of mice involved in the assays. 
types of erythrocytes. The degree of cross-reactivity between SRBC and HRBC 
was reported to be slight  (13),  as is also evident from the results in Table I. 
Effects of Lymphoid Cells on the Tolerant State.--Attempts were made to break 
tolerance to SRBC in mice pretreated 3 wk before with SRBC and cyclophos- 
phamide, by giving normal lymphoid cells from various sources. The results of a 
time course study on the 19S and 7S PFC response of SRBC-tolerant recipients 
given lymphoid cells are shown in Fig. 4, and the peak responses are statistically 
analyzed in Table II. It can be seen that bone marrow did not break tolerance. 
On the other hand, a significant elevation of the anti-SRBC 19S PFC response 
was obtained in SRBC-tolerant recipients given either thymus, thoracic duct, or 
normal spleen cells,  or given a mixture of thymus or thoracic duct lymphocytes 
and bone marrow. These responses were by no means restored to normal (Fig. 6- 
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FIG. 4.  Direct and developed PFC produced in the spleens of CBA mice challenged with 
SRBC 3 wk after pretreatment with SRBC and cyclophosphamide and given 2  X  107 marrow 
cells (v3  [~),  10 s thymus cells (O  O), 2  X  107 thoracic duct cells (Q----O), 4  X  107 
normal  spleen  cells  H,  or  a  mixture  of  2  X  107  marrow  and  108  thymus 
cells (O .... O), 2  X  10 v marrow and 2  X  10 v thoracic duct cells (O---O),  108 thymus cells 
and 2  X  107 spleen cells from adult thymectomized, irradiated  mice  (O .... O)  or 2  X  107 
thoracic duct cells and 2  X  107 spleen cells from such mice (O .... Q).  A  A  PFC response 
of normal mice of the same age. The number of mice per point was from 3  to  15. The peak 
responses are analysed statistically in Table II. 
682 
DEVEI_OI:ED  l~C J.  F.  A.  P.  MILLER  AND  G.  F.  MITCHELL  683 
4). Furthermore, only a few of the 7S PFC responses in the various groups were 
elevated significantly. 
It is known that mice which have been thymectomized in adult life, irradiated 
with a  lethal dose of X-ray, and protected with bone marrow cannot give a 
normal  anti-SRBC  response.  Sham-thymectomized irradiated  mice,  by  con- 
trast, recover the capacity to produce a significant PFC response after 2-3 wk 
(14,  and see below). Thymectomized irradiated, marrow-protected mice  lack 
thymus-derived cells but can be reconstituted to give a normal PFC response to 
SRBC by an injection of thoracic duct lymphocytes (5). The PFC, in this sys- 
tem, are derived not from the injected thoracic duct lymphocytes, but from the 
TABLE  II 
Peak PFC Response of CBA Mice Challenged with SRBC and Given Various  Types of Lymphoid 
Cdls 2-3 Wk after Pretreatment  with SRBC and  Cyclophosphamide 
Group 
9 
10 
Cells inoculated 
SRBC 
2X  107BM+SRBC 
10  a T  +  SRBC 
lO  a T  +  2 X  107BM +  SRBC 
108 T  +  2 X  107TxS +  SRBC 
2 X  107 TDL -b SRBC 
2 X  107 TDL +  2 X  10 7 BM + 
SRBC 
2 X  107TDL+2  X  107TxS+ 
SRBC 
2 X  107TxS +  SRBC 
4 X  10  7 normal S +  SRBC 
Peak 19S PFC count (4-5 
days after challenge) 
PFC/spleen 
9,80(1,160-820)*  (22)~ 
1,660(2,120-1,310)  (14) 
2,550(3,030-2,140)  (14) 
3,700(4,650-2,940)  (14) 
4,580(5,370-3,910)  (5) 
2,580(2,970-2,240)  (16) 
5,310(6,520-4,330)  (15) 
9,260(1.1070-7,750)  (8) 
2,200(2,490-1,960)  (7) 
5,070(6,470-3,970)  (18) 
P 
values, 
cf. 
group 1 
NS 
<0.05 
< 0. 005 
< 0. 005 
< 0. 005 
<0. 005 
<0. 005 
<0.05 
<0.0O5 
Peak 7S PFC count (6-7[ ~ 
days after challenge)  ~,~ 
PFC/spleen  ] 
260(330-200)*  (5)  -- 
230(310-180)  {5)  NS 
830(1,030-670)  (7)  <0.05 
3,260(4,480-2.380)  (8)  <0.05 
2,590(2,740-2,440)  (4)  <0.05 
820 (I,170-580)  (4)  NS 
1,420(1,770-1,150)  (4)  NS 
7,110(8,740-5,790)  (4)  NS 
190(220-170)  (4)  NS 
2,360(3,310-1,680)  (7)  <0.05 
* Geometric mean, upper and lower limits of SE. 
Single number in brackets refers to number of mice involved in the assays. 
marrow used to protect the mice from the lethal effects of irradiation. Hence, 
the cells which become 19S PFC  are not thymus-derived but can respond to 
SRBC only after interacting with thymus-derived cells.  It was thus of interest 
to show whether spleen cells of adult  thymectomized irradiated donors could 
interact with thymus or thymus-derived cells to produce a response to SRBC in 
SRBC-tolerant mice. As can be seen from Table II and Fig. 4, such spleen cells 
increased the  19S  PFC  response of SRBC-tolerant mice slightly when given 
alone, but to a greater extent when given with thymus or thoracic duct cells. 
From a consideration of these results as a whole, the question may be raised as 
to whether target  cells for tolerance induction  are present  in  both  thymus- 
derived and non-thymus-derived (marrow-derived) lymphoid cells. 
Induction of Tolerance in Thymus-Derived Lymphoid Cells.--CBA mice, given 
SRBC and cyclophosphamide 3 wk before, were used as donors of thymus or 684  CELL  TO  CELL  INTERACTION  IN  IMMUNE  RESPONSE.  V 
thoracic duct lymphocytes in cell  transfer  experiments.  Mice pretreated  with 
only cyclophosphamide served as control donors. Recipients were either neona- 
tally thymectomized,  or lethally irradiated and given bone marrow.  20 million 
thymus cells obtained from SRBC-tolerant donors were as effective as 2  X  107 
thymus cells from cyclophosphamide-treated controls in elevating the 19S PFC 
response of neonatally thymectomized recipients challenged with SRBC (Table 
III). This suggests that the tolerization regime did not induce tolerance at the 
TABLE  III 
19S PFC Produced in the Spleens of Neonatally  Thymectomized CBA  Mice  after Injection  of 
SRBC and Thymus  Cells from Normal Donors or from Mice Pretreated 8  Wk Previously 
with Either Cydophosphamide Alone or SRBC and Cydophosphamide 
Num- 
ber 
of  neo- 
natally  19S PFC count at 4-5  P values  Thymus cell  Cells inoculated  thy-  donor  days after challenge  mecto- 
mized 
recip- 
ients 
Normal 
Cyclophos- 
phamide 
pretreated 
SRBC- 
cyclophos- 
phamide 
pretreated 
PFC/spleen 
SRBC  12  710(940-540)*  ] 
k  <0.005 
2  X  107 T  +  SRBC  12  15,540(18,720-12,910)I 1 
t  Ns 
2  X  107T +  SRBC  6  13,350(18,300-9,750)  l) 
i 
2 X  107T+  SRBC  12  12,610 (15,930-9,980) 
NS 
* Geometric mean, upper and lower limits of SE. 
level of the lymphocytes differentiating within the thymus. The PFC  response 
in  neonatally  thymectomized  mice given  20 million thymus cells was slightly 
lower  than  that  previously  reported  (4).  This  may  be  because  the  mice 
used here as donors of thymus cells were,  on the average,  1 month older than 
those used in the previous studies. 
The failure  to achieve  tolerance  at  the level  of  the lymphocyte population 
within  the  thymus  was  further  substantiated  in  experiments  with  irradiated 
mice in which 5  X  107 thymus cells were given together with 2  X  l07 marrow 
cells. The same PFC response was achieved whether the thymus cells were ob- 
tained  from  normal,  cyclophosphamide-treated,  or  SRBC-tolerant  donors 
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The failure to achieve specific tolerance at the level of the thymus lymphocyte 
population  could  result  from  insufficient penetration  of  the  thymus  by the 
SRBC antigens capable of inducing tolerance. We therefore devised experiments 
to determine whether the mobile pool of thymus-derived cells could behave as a 
tolerant population. The capacity of thoracic duct cells from SRBC-tolerant 
mice to transfer SRBC reactivity adoptively was tested by injecting 10 million 
cells into 3-5-wk old neonatally thymectomized mice. Other thymectomized 
TABLE IV 
lOS PFC Produced in the Spleens of Heavily Irradiated  CBA Mice after Injection of SRBC and 
HRBC, Normal Bone Marrow Cells, and Thymus Cells from Normal Donors or from Mice 
Pretreated 8 Wk Previously with Cyclophosphamide Alone or SRBC 
and Cyclo ~hosphamide 
Normal 
Normal 
Thymus 
cell donor 
Cyclophos- 
phamide pre- 
treated 
SRBC-cyclo- 
phospham- 
ide pre- 
treated 
Cells inoculated 
2 )< 107 BM +  SRBC +  HRBC 
5 X 107T+SRBC+HRBC 
5 X  10  ¢ T +  2 X 107 BM + 
SRBC +  HRBC 
5 X  107T+2  X 107BM+ 
SRBC +  HRBC 
5 X 107T+2)<  10rBM+ 
SRBC +  HRBC 
* Geometric mean, upper and lower limits of sE. 
z~  19S PFC count at 8 days 
Anti-SRBC  P  Anti-HRBC  P  values  values 
PFC/spleen 
Io(~5-s>*  1 
8  1270(1600-1010)]  j 
~  NS 
8  1360(1810-970)  J] 
NS 
7  1430(1680-1210)  J 
PFC/spleen 
5(8-1)* 
NS 
15 (20-10 ) 
<0.05 
100(165--65) 
120(170-90)  N~S 
270 (350-210 
mice of the same age received an equivalent number of cells from cyclophos- 
phamide-treated control mice. The mice were challenged with either SRBC or 
HRBC or both antigens simultaneously. The number of 19S PFC in the spleens 
of the recipients was determined 4-5 days later and the results are shown in 
Table V. Thymectomized mice inoculated with  10 million thoracic duct cells 
from tolerant mice produced an average of 9,000-16,000 anti-SRBC PFC per 
spleen, whereas those receiving the same number of thoracic duct cells from con- 
trol mice had  an average response of 46,000-53,000  PFC.  This difference is 
statistically significant (P <  0.05). On the other hand, 10 million thoracic duct 
cells from both  tolerant and  control mice increased the  average response of 
thymectomized mice challenged with HRBC  to values exceeding 25,000 PFC 
per ~pleen.  The anti-SRBC response of recipients of SRBC  and lymphocytes 686  CELL  TO  CELL  INTERACTION  IN  IMMUNE  RESPONSE.  V 
from tolerant mice was increased slightly by a simultaneous injection of HRBC. 
This increase in the  average number of PFC per spleen from approximately 
9,000 to 16,000 is not statistically significant. 
It is evident that thoracic duct cells from SRBC-tolerant mice were inferior 
to cells from nontolerant donors in  adoptively transferring reactivity to the 
specific antigen used for tolerization. Nevertheless, they did increase the PFC 
response of neonatally thymectomized mice to SRBC. It may be that among the 
TABLE V 
19S PFC Produced  in the Spleens  of Neonatally  Thymectomized  CBA Mice after Injection of 
SRBC or HRBC and  Thoracic Duct Lymphocytes  from Mice Pretreated 3 Wk before with 
Either Cyclophosphamlde  Alone or SRBC and Cydophosphamide 
Thoracic duct  Cells inoculated 
cell donor 
Z 
19S  PFC count  at  4-5  days 
Anti-SRB C  Anti-HRB C 
PFC/spleen  PFC/spleen 
SRBC  12  1,100(1,380-880)*  -- 
HRBC  7  --  1,840(2,530-1,340) 
SRBC +  HRBC  7  1,770(3,230-970)  620(1,030-370) 
Cyclophos-  10  ~t TDL +  SRBC  9  53,310(66,780-42,550)5  -- 
phamide pre-  107 TDL +  HRBC  5  --  33,680(40,170-28,240) 
treated  107 TDL +  SRBC +  HRBC  9  46,110(58,450-36,380)§  25,680(34,100-19,340) 
SRBC cyclo-  107 TDL +  SRBC  10  9,200(12,160-6,950):~,H  -- 
phosphamide  107 TDL +  HRBC  4  --  28,750(37,980-21,760) 
pretreated  107 TDL +  SRBC +  HRBC  17  15,930(19,190-13,220)§,  ]1  26,540(31,320-22,480) 
*  Geometric mean, upper and lower limits of sE. 
:~, § P  <  0.05. 
II N.S. 
panel of donors cannulated to provide thoracic duct lymphocytes, a few were 
much less tolerant than others. This could account for the increase in the re- 
sponse of neonatally thymectomized recipients. It is also evident that the PFC 
response of neonatally-thymectomized mice given 10 million thoracic duct cells 
from 12-wk old cyclophosphamide-treated donors, was higher than that pre- 
viously recorded in  neonatally thymectomized recipients of normal  thoracic 
duct lymphocytes from 6 to 8-wk old donors (4). This may be due to the age 
difference between the two sets of donors, or it may be a consequence of the 
recovery from cyclophosphamide. 
Since the neonatatly thymectomized hosts provide the PFC precursors (4), 
the above results indicate that tolerance is a property that can be linked specifi- J.  ]?.  A.  P.  MILLER  AND  G.  l?.  MITCHELL  687 
cally to thymus-derived ceils.  Attempts were next made to determine whether 
or not target cells for tolerance induction  exist in the non-thymus-derived cell 
population. 
Induction of Tolerance in :Vonthymus-Derived (Marrow-Derived) Lymphoid 
Cells 
In order to determine whether target cells for tolerance induction  also exist 
in the nonthymus-derived cell population, two experimental designs were used. 
In the first, normal thymus cells were transferred into heavily irradiated mice 
together with either marrow cells or lymph node cells from normal donors or 
from mice pretreated with either cyclophosphamide alone or SRBC and cyclo- 
phosphamide 3 wk before. The PFC response of these mice to SRBC and HRBC 
was determined  8  days later.  In the  second  system,  attempts were made to 
produce a  specific tolerance to SRBC  in the lymphoid cell population of thy- 
mectomized irradiated, marrow-protected mice which  contain  PFC  precursors 
(5). 
Effects of Inoculating Irradiated Hosts with Mixtures of Normal  Thymus or 
Thoracic Duct Cells and Marrow or Lymphoid  Cells from Normal  or  Tolerant 
Donors.--Heavily  irradiated  mice were injected with SRBC,  5  X  107 normal 
thymus cells and 2 X  107 marrow cells from either normal, cyclophosphamide- 
pretreated donors, or SRBC-tolerant donors. The results in Table VI show that 
2 X  107 marrow cells obtained from SRBC-tolerant donors were as effective as 
2 X  l0  T marrow cells from cyclophosphamide-treated controls in elevating the 
19S PFC  response of heavily irradiated recipients. It is thus obvious that the 
tolerization regime had no effect upon those cells, present in bone marrow, which 
could, upon transfer to irradiated hosts, differentiate to cells which collaborate 
with thymus cells to produce a response to SRBC. The marrow is known to be a 
rich source of multipotential stem cells and may thus not be the ideal tissue in 
which to demonstrate tolerance at the level of the nonthymus-derived lympho- 
cyte population. A tissue lacking stem cells,  such as lymph node, was therefore 
examined. Irradiated mice received mixtures of lymph node and thymus cells or 
thoracic duct cells together with SRBC and HRBC. The donors of the thymus 
or thoracic duct cells were normal mice but the donors of the lymph node cells 
were either normal, SRBC-tolerant  (normal mice pretreated 3 wk before with 
SRBC and cyclophosphamide), or mice subjected 3 wk before to thymectomy, 
irradiation,  and marrow protection. Lymph node cells from mice of the latter 
group could be expected to lack thymus-derived cell.  The results of these ex- 
periments are shown in Table VII. Lymph node cells from thymectomized ir- 
radiated mice failed to adoptively transfer immune reactivity to either SRBC or 
HRBC in irradiated recipients. Addition of thymus cells or of thoracic duct cells 
increased the response to about 1000  and 6000 PFC per spleen in the case of 
SRBC and to about 200 and 1000 in the case of HRBC. Lymph node cells from 688  CELL TO CELL INTERACTION IN IMMUNE  RESPONSE. V 
SRBC-tolerant mice adoptively transferred immune reactivity to HRBC but 
not to SRBC. Normal lymph node cells,  on the other hand,  were capable of 
transferring reactivity to both SRBC and HRBC. A mixture of tolerant lymph 
node cells and thymus cells enabled irradiated recipients to respond to SRBC by 
producing some 600 PFC per spleen. This implies that collaboration between 
thymus cells and non-thymus-derived lymphocytes supplied from lymph nodes 
of SRBC-tolerant mice took place in the irradiated host. Furthermore, when a 
mixture of thoracic duct cells and lymph node cells was injected, the PFC re- 
TABLE  VI 
19S PFC Produced in the Spleens  of Heavily Irradiated  CBA Mice after Injection of SRBC and 
HRBC, Normal Thymus Cells, and Bone Marrow Cells from Normal Donors or from Mice 
Pretreated ~ Wk Previously  with Either Cyclophosphamide  Alone 
or SRBC and Cyclophosphamide 
Marrow cell 
donor 
Normal 
Normal 
Cyclophos- 
phamide pr~ 
treated 
SRBC-cyclo- 
phospham- 
ide pre- 
treated 
Cells inoculated 
5 X  107 T -]- SRBC +  HRBC* 
2 X  107 BM -1- SRBC -[- HRBC* 
2X107BM-I-s X10  ~T+SRBC 
+ HRBC* 
2 X 10  ~ BM +  5 X 10  ~ T q- SRBC 
-b  HRBC 
2X107BMff-5  X107T+ SRBC 
q- HRBC 
~a  ~'~ 
~'~ 
1121 
14 
8 
7 
19S PFC count at 8 days 
Anti-SRBC  P  Anti-HRBC  P  values  values 
PFC/spleen 
20(25-15)~ 
NS 
10(15-5) 
:0.005 
1270(1600-10101 
NS 
920(1100-770) 
NS 
1120(1380-910) 
PFC/spleen 
15 (20-10)~  IN S 
s(s-1)  )J<  . 
I,  0.05 
I00 (165-65)  t  NS 
200 (330-130)]IJ  NS 
n0(220-s0) ] 
* Data from Table IV. 
:~ Geometric  mean, upper and lower limits  of sE. 
sponse was essentially" of the same order of magnitude whether the lymph node 
cells were derived from tolerant donors or from adult thymectomized irradi- 
ated  mice.  Clearly,  therefore,  non-thymus-derived  cells  in  lymph nodes of 
SRBC-tolerant  mice  were  capable  of  interacting  effectively with  thynms- 
derived cells in thoracic duct lymph to produce a response not only to HRBC 
but also to SRBC. 
Attempts  to  Induce  Tolerance  in  Thymectomized  Irradiated,  Marrow-Pro- 
tected Hosts.--The above experimental design failed to demonstrate the exist- 
ence  of specific target  cells for tolerance induction  among  the  nonthymus- 
derived lymphocyte population of the lymph nodes. Therefore, either such cells 
do not exist so that the only cells capable of dictating the specificity of the re- 
sponse must be thymus-derived, or alternatively, tolerance had been achieved in J. F. A. P. MILLER AND G. F. MITCHELL  689 
the non-thymus-derived cell line but,  after transfer to irradiated hosts,  cells 
with new reactivity patterns were generated from thymus-independent lymph- 
oid stem cells. Attempts were thus made to induce tolerance in thymectomized 
irradiated, marrow-protected mice at a time after irradiation when regeneration 
of the thymus-independent lymphoid system could be expected to be complete. 
TABLE VII 
19S PFC Produced in the Spleens  of Heavily Irradiated  Mice after Injection of SRBC, HRBC, Normal 
Thymus, or Thoracic Duct Lymphocytes  and Lymph Node Cells from Normal, SRBC-Tolerant 
or Th  ~  mectomized Irradiated  Donors 
LN cell 
donor 
:BM 
RBC- 
tolerant 
ormal 
Cells inoculated 
2 X  107LN+SRBC+ 
HRBC 
2 X  107LN+5  X 10v T+ 
SRBC +  HRBC 
2 X  107LN+ 10~ TDL+ 
SRBC +  HRBC 
2 X 107LN+SRBC+ 
HRBC 
2X 107LN+5)<  10r T+ 
SRBC +  HRBC 
2 ×  107LN+ 107TDL+ 
SRBC +  HRBC 
2 X  107LN+SRBC+ 
HRBC 
2 )< 107 LN +  5  X  107 T  + 
SRBC +  HRBC 
2 X  107LN+107  TDL+ 
SRBC +  HRBC 
Num- 
ber of 
irra- 
diated 
recip- 
ients 
5 
5 
12 
14 
14 
17 
12 
SRBC +  HRBC 
10~ TDL +  SRBC +  HRBC 
19S PFC count at 7-8 days 
Anti- SRBC  P values 
18 
5 
5 
* Geometric mean, upper and lower limits of sz, 
PFC/spleen 
4(7-2)*  ~  / 
~<o.o5  [ 
980(1,500-640)  J  F<0.05 
5,510(7,090-4,280)  j 
50(70-40)  l<0.005/ 
61o(840-4so)  J  I<o.oos 
6~970(9,320-5,220)  J 
1,600(1,870-1,360) 1 
2,200(2,660-1,820)7  S 
8,350(10,080-6,920) 
Anti-HRB C  P values 
10(15-4) 
1,130(1,350-900) f <0.05 
PFC/spleen 
2(2.5-i)*  )jlN  s 
160 (200-90) 
950 (1,060--850) 
360(440-290)  1 
560(690-460)  j}NS 
3,080(3,990-2,380) 
400(490-330)  ItNS 
<0.005 7so0,000-s60) 
J  2,270 (3,050-1,690) 
<0.05 
J 
'<0.00. 
I 
<O.O0. 
5(8-2)  } 
560(640-490)  <0.05 
Mice thymectomized in adult life and subjected to irradiation and marrow 
protection were challenged with  SRBC  at various intervals of time after  ir- 
radiation and the splenic PFC response was determined 5 days after challenge. 
The results shown in Fig. 5 clearly demonstrate that adult thymectomy pre- 
vents the postirradiation recovery of the capacity to produce a significant 19S 
PFC  response to SRBC.  For up  to  10  wk  after irradiation,  groups  of these 
thymectomized mice could not produce an average PFC response higher than 
3 X  103 per spleen. It has been shown that in these mice, an injection of thoracic 
duct lymphocytes significantly elevated the PFC response and that the PFC's Z 
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were derived  not from the  inoculated lymphocytes, but  from precursors de- 
rived from the marrow given after irradiation (5). Attempts to induce tolerance 
in this particular marrow-derived lymphoid cell population were made by treat- 
ing adult thymectomized, irradiated,  marrow-protected mice with SRBC and 
4- 
WEEKS  AFTER  IRRADIATION 
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Fro. 5. PFC produced in the spleens of sham adult thymectomized  (0) and adult thymec- 
tomized (A) CBA mice at various times after receiving 900 rads total body irradiation and 10 
million syngeneic bone marrow cells. Splenic PFC were enumerated 4-5 days after the chal- 
lenge injection of SRBC. The number of mice per point was from 2 to 7 and the magnitude of 
twice the standard error is indicated by the length of the vertical bars. 
cyclophosphamide 3--4 wk after irradiation. As these thymectomized irradiated 
mice are unresponsive to heterologous erythrocytes (since they lack thymus- 
derived cells),  tests for specific tolerance to SRBC can be made only after pro- 
viding thymus-derived cells. If specific tolerance had been induced to SRBC in 
the  marrow-derived lymphoid cell  population,  it  would be  expected  that  no 
significant increase in the PFC response could be produced after an injection of 
thoracic duct lymphocytes in thymectomized irradiated mice pretreated 3 wk 
before with SRBC and cyclophosphamide. The results of such an experiment J.  F.  A.  P.  MILLER  AND  G.  F.  MITCHELL  691 
are shown in Table VIII. It is evident that thoracic duct lymphocytes elevated 
the  PFC  response  of thymectomized irradiated mice markedly  and  just  as 
effectively whether the recipients had been pretreated with SRBC-cyclophos- 
phamide or not. On the other hand, cells from the same thoracic duct lympho- 
cyte pool increased only slightly the anti-SRBC PFC response of normal mice 
given the tolerization regime. 
Hence, the data obtained in thymectomized irradiated mice do not determine 
whether tolerance was effectively induced and broken, or whether tolerance was 
TABLE VIII 
19S PFC Produced  in the Spleens  of Normal and  Adult  Thymectomized  Irradiated  Marrow-Protected 
CBA Mice Given Normal Thoracic Duct Lymphocytes  and Challenged with SRBC and 
HRBC 3 Wks after Pretreatment  with SRBC and Cyclophosphamide 
Treatment of 
recipients 
TxBM 
TxBM followed 3 
wks later by 
SRBC and cy- 
clophosphamide 
Normal mice 
given SRBC 
and cyclophos- 
phamide 
Cells inoculated 
SRBC +  HRBC 
2 X  107 TDL +  SRBC 
+  HRBC 
SRBC +  HRBC 
2 X  107 TDL, +  SRBC 
+  HRBC 
SRBC +  HRBC 
2 X 107TDL, +  SRBC 
+  HRBC 
,f 
ic 
el 
bu 
19S PFC count at 5 days 
Anti-SRB C  P  Anti-HRB  C  P  values  values 
PFC/spleen 
560(680-470)* 
50,950(61,150--42,450) 
280(440-180) 
46,850(58,480-37,530) 
2,250(2,430-2,080) 
4,800 (5,340-4,320) 
<0.05 
<0.00.' 
<0.05 
PFC/spleen 
290(490-170)* 
34,780(38,460-31,450) 
500 (680-360) 
27,070(32,700-22,400) 
32,430(62,020-44,320) 
43,100(53,820-34,520) 
<0.05 
<0.005 
NS 
* Geometric mean, upper and lower limits of sE. 
~: The same pool of TDL was used for these recipients. 
not achieved because it cannot be induced in the population of nonthymus- 
derived cells. The possibility that the induction of tolerance, like the induction 
of antibody formation in antibody-forming cell precursors, is facilitated by the 
presence of thymus-derived cells was investigated.  Thymectomized irradiated 
mice protected with bone marrow were given 10  s thymus cells intravenously 
and SRBC intraperitoneally 1 day later. 2 days after treatment with SRBC, 
they received cyclophosphamide subcutaneously. Controls received no thymus 
cells. 3 wk later, all mice received 15 )<  106 thoracic duct lymphocytes, SRBC, 
and HRBC intravenously and the peak number of PFC in their spleens was 
determined. The results given in Table IX indicate that the PFC response was 
of the same order of magnitude in thymectomized irradiated mice whether or 
not they had received thymus cells before treatment with SRBC and cyclophos- 692  CELL  TO  CELL  INTERACTION  IN  IMMUNE  RESPONSE.  V 
phamide.  It appears,  therefore, that induction of tolerance was  not achieved 
in the presence of thymus cells. 
DISCUSSION 
It is clear from the experimental evidence given in earlier papers of this series 
(4, 5, 7) that the non-thymus-derived ("marrow-derived") lymphocyte can pro- 
duce the hemolysin-forming cell in the response of mice to SRBC after interac- 
tion with  thymus-derived cells.  What  then is the role of the thymus-derived 
lymphocytes--the cells which never become the antibody-forming cells that are 
TABLE IX 
PFC Response of  Thymectomized Irradiated Mice  Pretreated with SRBC  and  Cyclophosphamide 
Day 1 
10ST 
10ST 
Day 2 
SRBC§ 
SRBC§ 
SRBC§ 
Day 
¢clop  )s- 
phar~  te 
¢clop  )s- 
pha~  le 
¢clop  )s- 
)ham  [e 
Nnm- 
I  ber  /  Day 21"  of 
mice  Anti-SRB C  P  values 
PFC/spleen 
SRBC +  HRBC  200(310-130)+  \<0.005 
1"5 X 107 TDL +  112  16'830(20'890-13'550) 1 
SRBC +  HRBC  INS 
1.5 X  107 TDL +  13,010(15,840-10,690) 
SRBC +  HRBC  <0.005 
SRBC -b HRBC  9  490(680-350) 
I9S PFC count 
Anti-HRBC  P  values 
PFC/spleen 
30 (50--20):~ 
/<0.005 
5,690 (6,620-4,890)}NS 
2,860(3,590.-2,280) 
~<0.005 
170(290-100)  J 
* Similar results were obtained when challenge was performed  on Day 12. 
:~ Geometric mean, upper and lower limits  of SE. 
§ Tolerance-induclng  dose. 
detected? The role of the  thymus-derived cell clearly hinges  on whether its 
influence in the response is specific or not, and whether antigen recognition is a 
property that can be linked to thymus-derived cells,  marrow-derived cells,  or 
both. The data available to date suggests  that  the influence of the thymus- 
derived lymphocyte is specific.  Two experimental approaches have shown spec- 
ificity at the level of "activation" of thymus lymphocytes by antigen. (a) In the 
first, a double transfer system was used. A first set of irradiated hosts received 
either SRBC alone, thymus cells alone, or thymus cells together with SRBC or 
HRBC. 7 days later,  a cell suspension from the spleens of the first irradiated 
hosts was injected into a second group of irradiated hosts together with marrow 
cells and SRBC and the response, in terms of PFC per spleen against SRBC was 
measured.  Only" those recipients of cells  that had  been "activated" with the 
same antigen--SRBC--could produce a significant PFC response (15). These 
results have been confirmed and extended in other investigations (3). (b) In the 
second set of experiments, published in this paper, thoracic duct cells  (which 
behave  essentially  as  thymus-derived  lymphocytes  in  reconstitution  exper- 7-  F.  A.  P.  MILLER  AND  G.  1~.  MITCHELL  693 
iments  (4)), were used.  Cells from mice specifically tolerant to SRBC,  adop- 
tively transferred immune reactivity to HRBC but not to SRBC in neonatally 
thymectomized recipients which themselves can supply the nonthymus-derived 
PFC precursors (4). It is evident, therefore, that tolerance is a property that 
can be linked to thymus-derived cells and that the thymus must produce uni- 
specific cells of the antigen-reactive type, each being sensitive to certain anti- 
genic determinants and to the induction of specific tolerance. 
No evidence could be obtained for the induction of tolerance to SRBC at the 
level of the lymphocyte population within the thymus itself. Thus thymus cells 
from SRBC-tolerant mice were as  effective as  thymus cells from controls in 
enabling neonatally thymectomized mice to respond to SRBC  and in collab- 
orating with marrow cells in irradiated mice. These results are in agreement 
with preliminary data published by Playfair (16) but not with results obtained 
from the experiments of Waksman and collaborators (17). These investigators, 
however, used  soluble antigens  such  as  bovine serum  albumin  (BSA)  which 
presumably, and in contrast to SRBC, diffuse readily within the thymus. Fur- 
ther evidence that tolerance can be achieved at the level of the thymus lympho- 
cyte population with soluble antigens, such as BSA, has recently been obtained 
by Taylor (8): thymus lymphocytes from mice treated with BSA were no longer 
capable of collaborating with marrow-derived cells in anti-BSA antibody pro- 
duction but were able to do so with respect to antibody production against 
human serum albumin. It is possible that if a soluble SRBC antigen were avail- 
able, tolerance at the level of the cell population within the thymus could be 
demonstrated. 
The indications that specific tolerance can be linked to thymus cells ill the 
case of soluble antigens and to thymus-derived cells (in thoracic duct lymph) in 
the case of insoluble antigens such as SRBC, do not support the various hy- 
potheses which would attribute to thymus-derived cells a passive or nonspecific 
role in the immune response, such as trephocytic or phagocytic. 
If the provision of nucleosides from thymus-derived cells was the only es- 
sential function of these cells in enabling the differentiation and proliferation of 
marrow-derived PFC precursors in response to antigens, one would not expect a 
tolerant population of thymus-derived cells to lack the capacity to subserve such 
a  nonspecific trophic function. Likewise, if thymus-derived  cells were simply 
the precursors of macrophages required to process nonspecifically the antigens of 
SRBC,  the population from tolerant animals  should have performed just  as 
effectively as that from controls. 
The data given here and in other publications (8)  indicate that the role of 
thymus-derived cells in the interaction is specific. A  crucial question is: since 
the marrow-derived cells  are the antibody-formers, are they also unispecific? 
Three experimental systems were used to provide an answer to this question: (a) 
attempts were made to break tolerance by injecting thymus-derived cells or 694  CELL  TO  CELL  INTERACTION  IN  IMMUNE  RESPONSE  V 
mixtures of thymus and non-thymus-derived cells; (b) the immune respanse of 
irradiated recipients of normal thymus cells and of marrow or marrow-derived 
lymphocytes from tolerant donors was studied, and (c) attempts were made to 
induce specific tolerance in thymectomized irradiated,  marrow-protected mice 
which lack thymus-derived cells.  Some increase in reactivity to SRBC was pro- 
duced in tolerant mice by thymus cells, thoracic duct lymphocytes, spleen cells, 
or a mixed inoculum of thymus or thoracic duct cells and marrow or marrow- 
derived  lymphoid  cells  (in  the  form  of  spleen  cells  from thymectomized  ir- 
radiated mice). It is not possible, however, to claim that tolerance was effectively 
broken by such  treatment.  Clearly,  some factor,  or factors,  other  than  both 
thymus and nonthymus cells,  must be supplied to the tolerant animal in. order 
to break tolerance more effectively. 
The second attempt to demonstrate the existence of target cells for tolerance 
induction in marrow-derived cells was made by transferring mixtures of marrow 
cells from tolerant donors and normal thymus cells into irradiated  mice. The 
results obtained do not agree with claims made by Playfair (16)  on the basis of 
preliminary evidence.  In  our system marrow cells from SRBC-tolerant  mice 
were  as  effective as  marrow  cells  from  cyclophosphamide-treated  donors  in 
collaborating with thymus cells in the response to SRBC in irradiated hosts. In 
Playfair's system marrow  cells  from  SRBC-tolerant  mice  taken  3  wk  after 
tolerance induction, when mixed with normal thymus cells,  allowed a response 
to SRBC in irradiated hosts which was 15% of that expected between normal 
marrow and  thymus cells.  Unfortunately, neither the response to a non-cross- 
reacting antigen in that particular group (which showed the greatest depression) 
was determined  nor  was  that  of irradiated  recipients  of normal thymus  and 
marrow from cyclophosphamide-treated controls.  Furthermore,  although  tol- 
erant donors still showed a  response to SRBC  between 8  and  15 %  of normal 
6-10 wk after tolerance induction,  mixtures of marrow from tolerant mice,  7 
wk after tolerance induction,  and normal thymus gave a response 86% of that 
expected in recipients of mixtures of normal cells in the case of SRBC and as low 
as 65 % in the case of chicken erythrocytes. It is difficult to conclude from such 
data that target cells for tolerance  induction  have been demonstrated in  the 
marrow population. It might be argued that tolerance cannot be demonstrated 
at the level of the marrow cell population simply because this populatioin con- 
tains multipotential stem cells which, upon transfer to heavily irradiated hosts, 
could  differentiate  to  cells with  new reactivity patterns.  Our data,  however, 
clearly demonstrate that tolerance cannot be revealed at the level of either the 
marrow cell  population  or  the  non-thymus-derived lymphoid cell population 
of the lymph nodes which lack such multipotential stem cells. Thus lymph node 
cells from either thymectomized irradiated  mice (which  lack  thymus-derived 
cells) or from SRBC-tolerant mice (in which the population of thymus-derived 
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almost as effectively with normal thymus or thoracic duct cells in allowing a 
response to SRBC  in irradiated recipients. The conclusion seems inescapable 
that  the  tolerization regime used  induced  tolerance only at  the  level of the 
thymus-derived cell population and not in the non-thymus-derived population. 
There was  no difference in  the  PFC  response of adult  thymectomized, ir- 
radiated  recipients  of  normal thoracic duct cells whether the hosts had been 
pretreated with SRBC and cyclophosphamide or not. It is thus impossible to 
decide whether or not tolerance had been induced in the marrow-derived lym- 
phocytes by such a regime. If it had, then, in contrast to the situation in normal 
animals, tolerance was effectively broken by thoracic duct cells. If this is so, it 
may be that failure to break tolerance in the normal animal is linked to the 
failure of adequate numbers of cells to penetrate the sites where antigen trig- 
gering occurs. Such a penetration would occur readily in an animal rendered 
lymphopenic by thymectomy and irradiation. It may well be, on the other hand, 
that tolerance could not be induced in the thymectomized irradiated  animal, 
because there are no target cells for tolerance induction in the marrow-derived 
cell population.  Alternatively,  such  cells might  be  present  but  induction  of 
tolerance, like induction of immunity, might require the presence of thymus- 
derived cells.  This suggestion receives support from findings obtained in thy- 
mectomized irradiated mice that were not treated with cyclophosphamide but 
given repeated doses of SRBC with or without thymus cells (18). In the present 
study, however, thymectomized irradiated mice pretreated with thymus cells 
immediately before the SRBC-cyclophosphamide regime, were not tolerant of 
SRBC when challenged 3 wk later.  Similar results, not shown here, were ob- 
tained when challenge was made 12 days later,  and when thymus cells were 
given instead of thoracic duct cells. 
The experiments described here have failed to provide a satisfactory answer 
to the most crucial question: are non-thymus-derived cells capable of dictating 
the specificity of the response? If it turns out that they are not, the possibility 
of information transfer must seriously be considered. It may be, for instance, 
that the genetic control of antibody synthesis has to be shared by two cell types: 
the nonthymus-derived cell could be differentiated so as to be capable of ex- 
pressing the information essential for the synthesis of that part of the immuno- 
globulin molecule which  determines  class  specificity; the  other cell could be 
thymus-derived  and  differentiated  so  that  it  could  express  the  information 
necessary for the synthesis of only the variable part of the molecule in which the 
specificity of the antibody combining site resides. Fusion of the two parts could 
occur in the non-thymus-derived cell after its interaction with the antigen-ac- 
tivated, thymus-derived cell, at the level of D NA or mRNA, as can be envisaged 
by various models. The particular genetic region determining antibody speci- 
ficity could exist in the episomal form. Once transferred to the marrow-derived 
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difficulties are, however, encountered with such information transfer theories, 
particularly when we consider that most humoral antibody responses are not 
thymus-dependent. One would have to postulate mechanisms  of information 
transfer from lymphocytes of the bursal equivalent system to marrow-derived 
cells.  Evidence for cell interaction in those responses not dependent upon the 
thymus is to date not available. 
Failure to demonstrate specific tolerance in the non-thymus-derived lymphoid 
cell lineage by no means  precludes the  existence of cells  in  this population, 
capable of dictating the specificity of the response. Treatment with SRBC and 
cyclophosphamide presumably leads  to  a  specific deletion of those  thymus- 
derived cells that  expand mitotically as  a  result of exposure to  SRBC. This 
could leave the marrow-derived lymphoid cell population intact and yet unable 
to respond since there are no specific thymus-derived cells with which to inter- 
act. Much recent evidence supports the concept that lymphocytes specifically 
absorb antigenic determinants (19, 20). It can thus be envisaged that thymus- 
derived cells specifically react with some of the antigenic determinants of sheep 
erythrocytes to carry these or other attached determinants into  appropriate 
sites where PFC precursors can be stimulated to produce the hemolysin response. 
At least two mechanisms can be envisaged. The first is based on the cellular 
events  occurring  during  bacterial  resistance  mediated  by macrophages  (21) 
and during delayed hypersensitivity. The activation of lymphocytes by certain 
antigens in delayed hypersensitivity reactions triggers the production of factors 
that  have  a  multitude  of biological activities--e.g,  the migration  inhibitory 
factor which acts on macrophages (22). Once elaborated, however, these factors 
have no immunological specificity. It may be,  therefore, that in immune  re- 
sponses  in  which  collaboration between thymus-derived and non-thymus-de- 
rived cells is required, the former are activated by antigen to produce factors 
which  facilitate  the  response  of  the  latter  to  other  antigenic  determinants. 
Facilitation may occur via the macrophage (possibly by enhancing the capacity 
of the macrophage to process the  antigen)  or by an  effect on the  antibody- 
forming cell precursors--e.g,  by enhancing the recruitment of these into the 
area where the antigen is deposited. The second mechanism can be called antigen 
focussing. This has been implicated in the immune response to hapten-protein 
conjugates in which one cell is carrier-reactive and the other hapten-sensitive 
(23, 24). Antigen focussing has also been implicated as occurring during immune 
responses  to heterologous erythrocytes and  serum  proteins,  responses  which 
require cell to cell interaction (1, 8, 25). The data presented in Table V do not 
support the contention that the production of an agent by activated thymus- 
derived cells is the sole mechanism involved in the collaboration between the 
two  cell types.  Thymus-derived cells  from  SRBC-tolerant  donors,  once  ac- 
tivated by HRBC, might be expected to produce a factor capable of promoting 
a response by antibody-forming cell precursors not only to HRBC but also to 
SRBC in a host injected with both erythrocytes. J.  F.  A.  P.  MILLER  AND  G.  F.  MITCHELL  697 
If  non-thymus-derived  lymphocytes are unispecific,  and  antigen-sensitive, 
some experimental system other than that involving tolerization by SRBC and 
cyclophosphamide, is required to demonstrate their existence. It is possible that 
induction of tolerance by some technique,  other than the cyclophosphamide in 
vivo method, such as, for instance, the use of judicious doses of soluble antigen 
in vivo or in vitro, might lead to the demonstration of the existence of specific 
non-thymus-derived cells. 
SUMMARY 
Collaboration  between  thymus-derived  lymphocytes,  and  nonthymus- 
derived antibody-forming cell precursors occurs during the immune response of 
mice to sheep erythrocytes (SRBC). The aim of the experiments reported here 
was to attempt to induce tolerance in each of the two cell populations to deter- 
mine which cell type dictates the specificity of the response. 
Adult mice were rendered specifically tolerant to SRBC  by treatment with 
one large dose of SRBC followed by cyclophosphamide. Attempts to restore to 
normal  their  anti-SRBC  response  by  injecting  lymphoid  cells  from various 
sources were unsuccessful. A slight increase in the response was, however, ob- 
tained in recipients of thymus or thoracic duct lymphocytes and a  more sub- 
stantial increase in recipients of spleen cells or of a mixture of thymus or thoracic 
duct  cells  and  normal  marrow  or  spleen  cells  from  thymectomized  donors. 
Thymus cells from tolerant mice were as effective as thymus cells from normal 
or  cyclophosphamide-treated  controls  in  enabling  neonatally  thymectomized 
recipients to respond to SRBC  and in collaborating  with normal marrow cells 
to allow a  response  to  SRBC  in  irradiated  mice.  Tolerance  was  thus  not 
achieved at the level of the lymphocyte population within the thymus, perhaps be- 
cause of insufficient penetration of the thymus by the antigens concerned. By 
contrast,  thoracic  duct  lymphocytes from tolerant  mice failed  to  restore  to 
normal the response of neonatally thymectomized recipients to SRBC. Toler- 
ance is thus a property that can be linked specifically to thymus-derived cells as 
they exist in the mobile pool of recirculating lymphocytes outside the thymus. 
Thymus-derived cells are thus considered capable of recognizing and specifically 
reacting with antigenic determinants. 
Marrow cells from tolerant mice were as effective as marrow cells from cyclo- 
phosphamide-treated or normal controls in collaborating with normal thymus 
cells to allow a response to SRBC in irradiated recipients. When a mixture of 
thymus or thoracic duct cells and lymph node cells was given to irradiated mice, 
the response to SRBC  was essentially the same whether the lymph node cells 
were derived from tolerant donors or from thymectomized irradiated, marrow- 
protected donors. Attempts to induce  tolerance  to  SRBC in adult  thymecto- 
mized, irradiated mice 3-4 wk after marrow protection, by treatment with SRBC 
and cyclophosphamide, were unsuccessful: after injection of thoracic duct cells, 
a vigorous response to SRBC occurred. The magnitude of the response was the 698  CELL  TO  CELL  INTERACTION  IN  I\iMUNE  RESPONSE.  V 
same whether  or not thvraus cells had  been  given priar to the talerization re- 
gime. 
The  various  experimental designs have  thus  failed  to  demonstrate  specific 
tolerance in the nonthymus-derived lymphocyte population. Several alternative 
possibilities were  discussed. Perhaps  such  a  population does not contain ceils 
capable of dictating  the  specificity of the  response.  This  was  considered un- 
likely. Alternatively, tolerance may have been achieved but soon masked by a 
rapid,  thymus-independent,  differentiation of marrow-derived lymphoid stem 
ceils. On the other hand, tolerance may not have occurred simply because the 
induction of tolerance, like the induction  of antibody formation,  requires  the 
collaboration  of  thymus-derived  cells.  Finally,  tolerance  in  the  nonthymus- 
derived cell population may never be  achieved because the  SRBC-cyclophos- 
phamide  regime specifically eliminates thymus-derived cells leaving the  anti- 
body-forming cell precursors intact but unable to react with  antigen as there 
are no thymus-derived cells with which to interact. 
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